The effect of combined thrombolysis with rtPA and tirofiban on ischemic brain lesions.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 15184627.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To determine the effect of systemic thrombolysis with low-dose recombinant tissue plasminogen activator (rtPA) and the body-weight adjusted platelet GPIIb/IIIa receptor antagonist tirofiban, the authors performed lesion volumetry on magnetic resonance perfusion and diffusion images recorded before thrombolysis and on T2-weighted magnetic resonance images on day 8. Treatment with rtPA and tirofiban (n = 13) resulted in a 50% lesion reduction (p < 0.03), while lesion reduction was less in rtPA treatment (n = 16) and absent in nontreated patients (n = 18).
Medical subject headings
- Brain Ischemia
- Infarction, Middle Cerebral Artery
- Thrombolytic Therapy
- Tissue Plasminogen Activator
- Tyrosine